Payment overview · 2025
General Payments
$642.76
25 reported records · 9 companies
Healthcare provider profile · identity verified
Bhupesh Sharma, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MI · NPI 1932273901
Verified facts
What the public records show
CMS Open Payments records show Bhupesh Sharma, MD received $642.76 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $297.60 | 46.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.83 | 26.9% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.38 | 10.0% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.78 | 3.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.42 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.00 | 3.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.68 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.20 | 2.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.87 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $642.76 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $224.34 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.83 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.26 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $64.38 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.00 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 286 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
159 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 28 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
286 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 433 | 79 |
| Famotidine | Famotidine | 368 | 79 |
| Losartan Potassium | Losartan Potassium | 347 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 298 | 55 |
| Jardiance | Empagliflozin | 286 | 60 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 272 | 58 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 251 | 52 |
| Metformin Hcl | Metformin Hcl | 243 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 42 |
| Tradjenta | Linagliptin | 197 | 31 |
| Simvastatin | Simvastatin | 179 | 31 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 172 | 29 |
| Furosemide | Furosemide | 161 | 35 |
| Farxiga | Dapagliflozin Propanediol | 159 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 154 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 141 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 139 | 27 |
| Trulicity | Dulaglutide | 112 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 105 | 33 |
| Carvedilol | Carvedilol | 101 | 23 |
| Januvia | Sitagliptin Phosphate | 100 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 27 |
| Glipizide | Glipizide | 93 | 22 |
| Glipizide Er | Glipizide | 91 | 19 |
| Meloxicam | Meloxicam | 90 | 51 |
| Montelukast Sodium | Montelukast Sodium | 90 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 21 |
| Omeprazole | Omeprazole | 80 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Allopurinol | Allopurinol | 69 | 18 |
| Entresto | Sacubitril/Valsartan | 67 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 28 |
| Sertraline Hcl | Sertraline Hcl | 61 | 12 |
| Gabapentin | Gabapentin | 60 | 18 |
| Valsartan | Valsartan | 59 | 16 |
| Pregabalin | Pregabalin | 56 | 12 |
| Eliquis | Apixaban | 55 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 53 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 53 | 15 |
| Lisinopril | Lisinopril | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 48 | 16 |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 44 | 14 |
| Ranolazine Er | Ranolazine | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Azithromycin | Azithromycin | 40 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 32 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 15 |
| Tramadol Hcl | Tramadol Hcl | 26 | 15 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 17 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Prednisone | Prednisone | 19 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $642.76 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, JARDIANCE, Kerendia, OPSUMIT, UPTRAVI, VERQUVO, VOQUEZNA, Wegovy, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error